RecBio Funding: $227M Raised, IPO (2022)

RecBio funding overview

RecBio is based in Taizhou, China. RecBio has raised $227M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is an IPO announced in April 2022. The round record for RecBio runs through 2022; nothing later has been disclosed. Investors on record include China Resources, Legend Holdings, Yangtze River Pharmaceutical Group, Harvest Global Investments, Sequoia Capital China, Temasek and 5 others. 11 distinct backers are named across the disclosed rounds.

RecBio at a glance

Total raised: $227M
Latest round: IPO
Latest round date: April 2022
Headquarters: Taizhou, China
Notable investors: China Resources, Legend Holdings, Yangtze River Pharmaceutical Group, Harvest Global Investments, Sequoia Capital China, Temasek, Lake Bleu Capital, Legend Capital

Frequently asked about RecBio funding

How much has RecBio raised?: RecBio has raised $227M in total disclosed funding across the rounds on record.
Who has invested in RecBio?: China Resources, Legend Holdings, Yangtze River Pharmaceutical Group, Harvest Global Investments, Sequoia Capital China, Temasek are named among the investors backing RecBio.
What was the latest RecBio funding round?: The most recent disclosed round is an IPO, announced in April 2022.
Where is RecBio based?: RecBio is based in Taizhou, China.
When did RecBio last raise?: The last disclosed RecBio round closed in April 2022 at IPO.

Every RecBio figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Taizhou at a similar stage.

RecBio Funding: $227M Raised, IPO (2022)

RecBio funding overview

RecBio at a glance

Frequently asked about RecBio funding

Companies related to RecBio (36)

Browse related funding lists (5)